Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Garber

Showing results (51-60 of 393) with videos related to

Pageof 40
Sort By:
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 27, 2015
ANTI-OBESITY PHARMACOTHERAPY AND THE POTENTIAL FOR PREVENTING PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETESAlan J Garber
Clinical Cornerstone|June 13, 2003
Cardiovascular complications of diabetes: prevention and managementAlan J Garber
Diabetes, Obesity & Metabolism|February 28, 2001
Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough?A J Garber
Diabetes Care|April 29, 2011
Incretin effects on β-cell function, replication, and mass: the human perspectiveAlan J Garber
Diabetes Care|April 29, 2011
Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerabilityAlan J Garber
The Journal of Clinical Investigation|September 1, 1978
The regulation of skeletal muscle alanine and glutamine formation and release in experimental chronic uremia in the rat: subsensitivity of adenylate cyclase and amino acid release to epinephrine and serotoninA J Garber
Expert Opinion on Investigational Drugs|November 25, 2011
Novel GLP-1 receptor agonists for diabetesAlan J Garber
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 15, 2004
Metformin: mechanisms of antihyperglycemic action, other pharmacodynamic properties, and safety perspectivesA J Garber
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 1, 1997
Dyslipidemia as a risk factor for coronary disease in patients with diabetesA J Garber
Journal of Diabetes|November 15, 2014
Biosimilar products are not bioidenticalAlan J Garber
Pageof 40

Showing results (51-60 of 393) with videos related to

Sort By:
Pageof 40
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 27, 2015
ANTI-OBESITY PHARMACOTHERAPY AND THE POTENTIAL FOR PREVENTING PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETESAlan J Garber
Clinical Cornerstone|June 13, 2003
Cardiovascular complications of diabetes: prevention and managementAlan J Garber
Diabetes, Obesity & Metabolism|February 28, 2001
Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough?A J Garber
Diabetes Care|April 29, 2011
Incretin effects on β-cell function, replication, and mass: the human perspectiveAlan J Garber
Diabetes Care|April 29, 2011
Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerabilityAlan J Garber
The Journal of Clinical Investigation|September 1, 1978
The regulation of skeletal muscle alanine and glutamine formation and release in experimental chronic uremia in the rat: subsensitivity of adenylate cyclase and amino acid release to epinephrine and serotoninA J Garber
Expert Opinion on Investigational Drugs|November 25, 2011
Novel GLP-1 receptor agonists for diabetesAlan J Garber
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 15, 2004
Metformin: mechanisms of antihyperglycemic action, other pharmacodynamic properties, and safety perspectivesA J Garber
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 1, 1997
Dyslipidemia as a risk factor for coronary disease in patients with diabetesA J Garber
Journal of Diabetes|November 15, 2014
Biosimilar products are not bioidenticalAlan J Garber
Pageof 40